Apogee Therapeutics, Inc. APGE Ratios & Valuation
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Returns | ||||
| Return on assets | -30.3%+1.3pp | -31.5%-1.2pp | -30.3%— | |
| Liquidity | ||||
| Current ratio | 26.6×+8.0× | 18.5×-0.8× | 19.4×+4.1× | |
| Quick ratio | 26.6×+8.0× | 18.5×-0.8× | 19.4×+4.1× | |
| Cash ratio | 4.7×-0.3× | 5×-0.8× | 5.8×-9.5× | |
| Leverage | ||||
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×— | |
| Valuation | ||||
| Market capitalization | $5.16B+100% | $2.58B+92.1% | $1.34B— | |
| Enterprise value | $5.03B+106% | $2.45B+99.8% | $1.23B— | |
| Free cash flow yield | -4.5%+2.2pp | -6.7%-1.1pp | -5.6%— | |
| Earnings yield | -5%+2.1pp | -7.1%-0.8pp | -6.3%— |
Questions, answered.
- Where do Apogee Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Apogee Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.